CEPMAGH. Optimal routes of administration of ergotamine tartrate in-cluster headache patients. A pharmacokinetic study* Introduction
|
|
- Leslie Baldwin
- 5 years ago
- Views:
Transcription
1 Optimal routes of administration of ergotamine tartrate in-cluster headache patients. A pharmacokinetic study* K. Ekbom, A. E. Krabbe, G. Paalzow, L. Paalzow, P. Tfelt-Hansen and E. Waldenlind CEPMAGH Ekbom K., Krabbe, A. E., Paalzow, G., Paalzow, L., Tfelt-Hansen, P. & Waldenlind, E : Optimal routes of administration of ergotamine tartrate in cluster headache patients. A pharmacokinetic study. Cephalalgia, Vol. 3, pp Oslo. ISSN Bioavailability and rate of absorption of ergotamine were studied in eight cluster headache patients outside attacks. In a cross-over design, approximately 2 mg ergotamine tartrate was administered as effervescent tablets, suppositories, and from an inhalation device, with 0.25 mg intravenously as the reference. Ergotamine in plasma was measured by high performance liquid chromatography with fluorescence detection from 5 to 420 min. For all three routes of administration, a similar low ( %) bioavailability of ergotamine was estimated. Only inhalation of ergotamine resulted in early (at 5 min) peak concentrations of ergotamine in plasma and is therefore most likely to relieve the short-lived attacks of cluster headache. The inhalation route for ergotamine poses problems, however, and we suggest ways of improving the inhalation device. 0 Cluster headache, ergotamine, pharmacokinetics. K. Ekbom, A. LE. Krabbe, G. Paalzow, L. Paalzow, P. Tfelt-Hansen and E. Waldenlind, Department of Neurology, Sodersjukhuset, Stockholm, Department of Pharmacology, Centrallaboratoriet, Apoteksbolaget AB, Solna, Sweden and Department of Neurology, Rigshospitalet, Copenhagen, Denmark. Correspondence and reprints requests to: P. Tfelt-Hansen, Department of Neurology, Rigshospitalet, D K-2100 Copenhagen 0, Denmark; Accepted 1982 I1 09. Introduction Ergotamine is generally regarded as the drug of choice for the treatment of cluster headache (1,2). Cluster headache attacks are of short duration ( min), so if a drug is to influence their natural course it has to be quickly available in the blood. In our experience ergotamine tablets are ineffective, whereas intravenous or intramuscular injections of ergotamine when effective give quick relief from attacks of cluster headache (within 2-15 mill, uncontrolled personal observation). Few patients can inject themselves, so an ergotarnine preparation which quickly reaches the blood would be valuable. Several ergotamine preparations-inhalator, effervescent tablets, sublingual tablets and fast dissolving tablets-have been developed to increase the rate of absorption. Because of the lack of suitable methods for determining the amount of ergotamine in * Presented in part at a Meeting of the Scandinavian Migraine Society, June 1981, Roros, Norway. the blood, neither the rate of absorption nor the amount of the drug absorbed have been documented. The aim of the present study was to investigate the rate and amount of ergotamine absorbed from an inhalation device, effervescent tablets, and suppositories. Intravenous ergotamine was also given to allow exact calculation of the bioavailability of ergotamine for these three forms of administration. Patients and methods Four male periodic cluster headache patients from each of our clinics were asked to join the study. Since they were to remain without any medication during the study period, they were selected as not being likely to have a cluster period within the following three months. Patients with hepatic, renal and cardiovascular diseases or with a history of dyspepsia were excluded. Thus, eight patients with a mean age of 35 years (range 23-61)
2 16 K. Ekborn et al. CEPHALALGIA 3 (1983) were studied. Routine blood chemistry including liver enzymes was normal in all patients. All gave their informed consent. Investigations of ergotamine administration were done at least at weekly intervals. The patients came to the clinic in the mornirg, having fasted since midnight. After a blood sample had been drawn they received 0.25 mg ergotamine tartrate* i.v. (Gynergen@, Sandoz), or 2 mg ergotamine tartrate plus 50 mg caffeine as an effervescent tablet (EffergotB, Wander) dissolved in 150 ml water, or 2mg ergotamine tartrate plus 100 mg caffeine as a suppository (Gynergen Caffeine@, Sandoz), or six puffs of 0.36mg each (a total of 2.16 mg) ergotamine tartrate within 2 min of an inhaler (Medihaler Ergotamine@, Riker). The inhalation technique was rehearsed several times with a dummy inhaler before the active drug was given. Blood samples were then drawn after 5, 10,20,30,60,120,180,240,300 and 420 min. Each time, 10ml blood was drawn and immediately centrifuged. Plasma was kept deep-frozen at -20 C until analysed. The analysis of ergotamine in plasma samples was performed with high performance liquid chromatography with fluorescence detection, using ergocristilie as the internal standard (3). The practical detection limit with a 3 ml sample was determined to be 0.1 ng/ml. Multiexponential equations were fitted to the obtained plasma concentration data after i.v. administration by the nonlinear least squares regression program NONLIN run on an IBM 370 computer. Pharmacokinetic parameters were calculated according to standard formulas (4). Area under the curve (AUC) for other routes of administration was calculated with the trapezoidal rule. Bioavailability was then calculated from the formula (e.g. for rectal AUCrectaI X D0sei.v. route) AUCi.v. X Doserectal In most cases the exact AUC could not be calculated (ergotamine undetectable) ~ so an * Ergotamine in solution is partly epimerised to a stereochemic isomer ergotaminine. Thus a solution of ergotamine tartrate contains 60% ergotamine and 40% ergotaminine. The dose used in the calculations of pharmacokinetic parameters and bioavailability has been corrected for this. estimate of the maximal possible AUC for 10 h was calculated with the use of 0.05 ng/ ml when ergotamine was undetectable. This estimate was then used for calculating the maximal possible bioavailability. The plasma concentration data were analysed statistically with two-sided analysis of variance for difference between administration forms. Results The pharmacokinetic parameters for i.v. ergotamine are shown in Table 1. The very low and variable concentrations of ergotamine in plasma after the other three routes of administration are shown in Tables 2-4. At 5 min the ergotamine concentrations obtained in plasma were significantly higher (p < 0.05, two-sided analysis of variance) after inhalation than they were after the other two routes of administration; later on, concentrations did not differ significantly. For inhalation the peak was observed at 5 min, the concentrations at this time always being higher than the later ones (p < 0.05, sign test). After inhalation the ergotamine concentrations declined in a seemingly biexponential manner as illustrated in Fig. 1. Calculation of bioavailability could be made in only three cases. For the rectal route the bioavailability of ergotamine was 2.8% in pt. no. 6 and for inhalation 3.3% (pt. no. 1) and 4.2% (pt. no. 3). In all other cases only the maximal possible bioavailability of ergotamine could be estimated. This estiaate of bioavailability had a mean value of x 0 C it Ergotarnine Pulmonal administration I min Fig. 1. Mean plasma concentration of ergotamine after inhalation of 2.16 mg ergotarnine tartrate in eight patients.
3 CEPHALALGIA 3 (1983) Ergotarnine for cluster headache 17 Table 1. Pharmacokinetic parameters for 0.25 mg ergotamine tartrate intravenously in eight cluster headache patients. Patient number Area under the plasma concentration curve ng X hr X ml+' Volume of distribution for the Pphase 1 x kg-' Plasma clearance 1 x kg-' x hr-' Half life for the Pphase hr Mean Range ~~ 3.91 ( ) ( ) ( ) ( ) Table 2. Ergotamine concentration (ndml) in plasma of eight patients after 2mg ergotamine tartrate as an effervescent tablet. Min after administration Pt. no ~ -~ Mean* Dashes: Concentration of ergotamine below the detection limit of 0.1 ng/ml. * In the calculation of the mean, levels below detection limit were given a value of 0.05 ng/ml Table 3. Ergotamine concentration (ndml) in plasma of eight patients after 2mg ergotamine tartrate as a suppository. Min after administration Pt. no ~ Mean* Notes: As for Table 2.
4 18 K. Ekbom et al. CEPHALALGIA 3 (1983) Table 4. Ergotamine concentration (ng/ml) in plasma of eight patients after 2.16 mg (six puffs) ergotamine tartrate by inhalation. Mn after administration Pt. no Mean* Notes: As for Table % (range 052.2%: n = 6) for inhalation, 1.8% (range %, n = 7) for suppositories, and 1.5% (range %, n = 8) for effervescent tablets. No side-effects were observed. Discussion Evidence from the literature of the rate of absorption from different ergotamine preparations was available and determined our choice of preparations for investigation. Effervescent ergotamine tablets containing caffeine were found suitable, since ergotamine in solution is absorbed in man with an invasion half life of 30 min (5), and caffeine should enhance the rate of absorption (6). Observations of the effect of ergotamine on temporal artery pulsations during migraine attacks indicated a quicker absorption of the drug from suppositories than from tablets (7). Inhalation of ergotamine was introduced in order to deliver the drug rapidly to the blood by transpulmonary absorption (8). Relief of migraine and cluster headache attacks has been reported to occur within 15min (8,9) with this route of administration. In our eight cluster headache patients the kinetic parameters of ergotamine after intravenous administration of 0.25 mg ergotamine tartrate are similar to our previous results with 0.5 mg intravenously in 10 mig- raine patients (10). The mean plasma clearance of X kg-' X h-', which varied four-fold in our patients, is similar to the mean value of X kg-' X h-*, which varied three-fold in migraine patients (10). There is thus no indication of a difference in metabolism and therefore pharmacokinetic studies on ergotamine should be comparable in these two groups of patients. Because of the very low concentrations of ergotamine in plasma, in most cases bioavailability of ergotamine could only be calculated as the maximal possible. In the three cases in which the bioavailability could be calculated it was 34%. This figure probably represents the real maximal values for ergotamine. In a previous study of ergotamine tablets no ergotamine was detectable in plasma with the present HPLC method and a maximal possible bioavailability of 1% was estimated (11). Studies on oral and rectal ergotamine administration, where radio immunoassay was used for ergotamine detection, showed somewhat higher plasma concentrations of the drug in plasma, but the bioavailability could not be calculated (12,13). The very low oral bioavailability of ergotamine is probably due to the extensive first-pass extraction by the liver, since 62% of orally administered ergotamine is absorbed (5). In a recent study on dihydroergotamine, a 9699% extraction by the liver of the drug absorbed resulted in an oral
5 CEPHALALGIA 3 (1983) bioavailability of 0.5% (14). In rectal administration the concentrations of ergotamine in plasma are marginally higher than after oral administration. This indicates that some of the rectally administered drug is absorbed to the systemic circulation, thereby escaping the first-pass extraction by the liver. The low bioavailability of ergotamine inhaled through using an aerosol is not surprising since the major part of a drug administered with the use of an aerosol is swallowed (15). The main purpose of the present study was to investigate the rate of absorptionthe time to peak concentration of ergotamine-of the three routes of administration. Estimating time to peak is difficult because of the very low concentrations of ergotamine obtained in plasma. For effervescent tablets the results give no indication of the time to peak. For suppositories the results indicate a time to peak of 60 min. A similar time to peak for ergotamine suppositories was found with a radio immunoassay for ergotamine (12). By contrast, inhalation of ergotamine resulted in a peak at 5min. This early peak and a similar mean plasma concentration curve seen after intravenous administration indicate an almost instantaneous delivery of ergotamine to the blood by the inhalation route. Buccal absorption of measurable amounts of ergotamine from aerosol particles deposited in the mouth is unlikely. Previously, we were unable to detect ergotamine in plasma for 2h after administration of 2 mg ergotamine tartrate as a sublingual tablet (16). The quick appearance of ergotamine in plasma after inhalation is therefore most likely due to transpulmonary absorption of ergotamine. Our present results indicate that, apart from injections of ergotamine, inhalation is the route of administration most likely to relieve the short-lived cluster headache attacks. But there are several problems with the inhalation of ergotamine. The technique is difficult even for such regular users of an aerosol as asthmatic patients (17). Even after practising the technique several times we found very variable plasma concentrations of ergotamine. Furthermore, a dose of 2.16 mg ergotamine tartrate requires as many as six puffs. Finally, the presently Ergotamine for cluster headache 19 available inhalation device is constructed to deliver an aerosol with the same particle size (median 3.5 pm) as used for bronchodilatator treatment. Ergotarnine in aerosol form is used to obtain a systemic effect and not a local effect in the bronchial tree. The particle size in the ergotamine aerosol might not therefore be optimal for this purpose. There is little knowledge about inhaled ergotamine in the treatment of cluster headache. Ergotamine inhalation was used in an open trial in 12 patients (9). Relief from pain was obtained within half an hour in 71% out of 114 attacks. Kudrow (1) mentions that of 100 patients treated, 79 had obtained significant relief from sublingual or inhalant ergotamine preparations. Since inhaled ergotamine was better than placebo in the treatment of migraine attacks (18), it is tempting to try to demonstrate its effect on cluster headache attacks in a controlled clinical trial. Before embarking on a comprehensive clinical trial we suggest that attempts should be made to optimize the dose of the single puff and also the particle size of the ergotamine aerosol. References 1. Kudrow L. Cluster headache. Mechanism and management. Oxford/New Yorfloronto: Oxford University Press, Ekbom K. Therapy of cluster headache. Migraine News 1974:27 3. Edlund P 0. Determination of ergot alkaloids in plasma by high performance liquid chromatography and fluorescence detection. J Chromatogr 1981 ;226: Wagner J G. Fundamentals of clinical pharmacokinetics. Drug intelligence publications. Illinois: Hamilton, Aellig W H, Niiesch E. Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man. Int J Clin Pharmacol Biopharm 1977;15: Schmidt R, Fanchamps A. Effect of caffeine on intestinal absorption of ergotamine in man. Eur J Clin Pharmacol 1974;7: Brazil P, Friedman A P. Further observations in craniovascular studies. Neurology 1957;7: Blumenthaler L S, Fuchs M. Transpulmonary absorption of ergotamine tartrate for vascular headaches. Med Ann D C 1961;30:1&13
6 20 K. Ekbom et al. CEPHALALGIA 3 (1983) 9. Graham J R, Malvea B P, Gramm H F. Aerosol ergotamine tartrate for migraine and Horton s syndrome. New Eng J Med 1960;263: Ibraheem J J, Paalzow, L, Tfelt-Hansen P. Kinetics of ergotamine after intravenous and intramuscular administration in migraine sufferers. Eur J Clin Pharmacol 1982;23: Ekbom K, Paalzow L, Waldenlind E. Low biological availability of ergotamine tartrate after oral dosing in cluster headache. Cephalalgia 1981;1: Ala-Hurula V, Myllyla V V, Arvela P, Heikkila J, Karki N, Hokkanen E. Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration. Eur J Clin Pharmacol 1979; 15: Ala-Hurula V, Myllyla V V, Arvela P, Karki N, Hokkanen E. Systemic availability of ergotamine tartrate after three successive doses and during continuous medication. Eur J Clin Pharmacol 1979 ; 16 : Little P J, Jennings G L, Skews H, Bobik A. Bioavailability of dihydroergotamine in man. Br J Clin Pharmacol 1982;13: Newman S P, Pavia D, Clarke S W. How should a pressurized Padrenergic bronchodilator be inhaled? Eur J Respir Dis 1981;62: Tfelt-Hansen P, Paalzow, L, Ibraheem J J. Bioavailability of sublingual ergotamine. Br J Clin Pharmacol 1982;13: Shim C, Williams Jr, M H. The adequacy of aerosol from cannister nebulizers. Am J Med 1980 ;69: Crooks J, Stephen S A, Brass W. Clinical trial of inhaled ergotamine tartrate. Br Med J 1964;1:221-4
Buccal absorption of ergotamine
Journal of Neurology, Neurosurgery, and Psychiatry, 1974, 37, 1116-11 Buccal absorption of ergotamine J. M. SUTHERLAND, W. D. HOOPER, M. J. EADE, AND J. H. TYRER From the Department of Medicine, Royal
More informationPharmacokinetics I. Dr. M.Mothilal Assistant professor
Pharmacokinetics I Dr. M.Mothilal Assistant professor DRUG TRANSPORT For a drug to produce a therapeutic effect, it must reach to its target and it must accumulate at that site to reach to the minimum
More informationPharmacokinetics of ibuprofen in man. I. Free and total
Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationships Ibuprofen kinetics were studied in 15 subjects after four oral doses. Plasma levels of both total and free ibuprofen were
More informationPreliminary studies of the pharmacokinetics and pharmacodynamics
Br. J. clin. Pharmac. (1987), 23, 137-142 Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers WENDY B. TAYLOR & D. N. BATEMAN Wolfson Unit of Clinical
More informationPharmacokinetic Phase
RSPT 2217 Principles of Drug Action Part 2: The Pharmacokinetic Phase Gardenhire Chapter 2; p. 14-25 From the Text Common Pathways for Drug Box 2-3; page 18 Plasma Half-lives of Common Drugs Table 2-4;
More informationOsnove farmakokinetike. Aleš Mrhar. Prirejeno po. A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne,
Osnove farmakokinetike Aleš Mrhar Prirejeno po A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne, College of Pharmacy, University of Oklahoma Pharmacokinetics/Pharmacodynamics Pharmacodynamics
More informationNontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment
Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment Please consider the following questions. If you do not feel confident about the material being covered, then it is recommended
More informationRoutes of drug administration
Routes of drug administration Definition:- A route of administration in pharmacy is the path by which a drug is taken into the body. Classification:- The various routes of administrations are classified
More informationPharmaceutics I صيدالنيات 1. Unit 2 Route of Drug Administration
Pharmaceutics I صيدالنيات 1 Unit 2 Route of Drug Administration 1 Routs of Drug administration The possible routes of drug entry into the body may be divided into two classes: Parenteral Rout Enteral Rout
More informationBrand and Generic Drugs. Educational Objectives. Absorption
Peter J. Rice, PharmD, PhD Associate Professor of Pharmacology East Tennessee State University Educational Objectives Pharmacokinetic Processes Distribution Metabolism Excretion Similarities Active ingredient(s)
More informationThe pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in.
Br. J. clin. Pharmac. (1987), 24, 493-501 The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More informationCHAPTER-I DRUG CHARACTERIZATION & DOSAGE FORMS
CHAPTER-I DRUG CHARACTERIZATION & DOSAGE FORMS by: j. jayasutha lecturer department of pharmacy practice Srm college of pharmacy srm university DRUG CHARACTERIZATION: Pre-formulation studies will attempt
More informationPharmacokinetic Phase
RSPT 2317 Principles of Drug Action Part 2: The Pharmacokinetic Phase Pharmacokinetic Phase This phase describes the time course and disposition of a drug in the body, based on its absorption, distribution,
More informationBiopharmaceutics Lecture-11 & 12. Pharmacokinetics of oral absorption
Biopharmaceutics Lecture-11 & 12 Pharmacokinetics of oral absorption The systemic drug absorption from the gastrointestinal (GI) tract or from any other extravascular site is dependent on 1. 2. 3. In the
More informationPHARMACOKINETICS OF DRUG ABSORPTION
Print Close Window Note: Large images and tables on this page may necessitate printing in landscape mode. Applied Biopharmaceutics & Pharmacokinetics > Chapter 7. Pharmacokinetics of Oral Absorption >
More informationOral Soluble Film Products for Epilepsy: Clobazam (COSF) and Diazepam (DBSF)
Oral Soluble Film Products for Epilepsy: Clobazam (COSF) and Diazepam (DBSF) Michael A. Rogawski, M.D., Ph.D. Professor of Neurology and Pharmacology School of Medicine University of California, Davis
More informationThe pharmacokinetics and dose proportionality of cilazapril
Br. J. clin. Pharmac. (1989), 27, 199S-204S The pharmacokinetics and dose proportionality of cilazapril J. MASSARELLA, T. DEFEO, A. LIN, R. LIMJUCO & A. BROWN Departments of Drug Metabolism and Clinical
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationThe excretion of zopiclone into breast milk
Br. J. clin. Pharmac. (1990), 30, 267-271 The excretion of zopiclone into breast milk I. MATHESON1, H. A. SANDE2 & J. GAILLOT3 'Department of Pharmacotherapeutics, University of Oslo, Oslo, 2Department
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationErgotamine/Dihydroergotamine Products
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationNANO 243/CENG 207 Course Use Only
L6. Drug Administration & Transport by Fluid Motion April 19, 2018 Part I: Drug Administration Routes of Drug Administration Topical: local effect, substance is applied directly where its action is desired.
More informationDetermination of bioavailability
Pharmaceutics 2 Bioavailability Bioavailability is the rate and extent to which an administered drug reaches the systemic circulation. For example, if 100 mg of a drug is administered orally and 70 mg
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More informationBioavailability and Related Pharmacokinetics in Man of Orally Administered L-5-Hydroxytryptophan in Steady State
Acra pharmacol. et roxicol. 1980, 46, 257-262. From the University Department of Neurology, the Research Laboratory for etabolic Disorders of the University Department of Clinical Chemistry, Aarhus Kornrnunehospital,
More informationUNIVERSITY OF THE WEST INDIES, ST AUGUSTINE
UNIVERSITY OF THE WEST INDIES, ST AUGUSTINE FACULTY OF MEDICAL SCIENCES SCHOOL OF PHARMACY BACHELOR OF SCIENCE IN PHARMACY DEGREE COURSE SYLLABUS COURSE TITLE: COURSE CODE: BIOPHARMACEUTICS, NEW DRUG DELIVERY
More informationPHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 FINAL EXAM FALL 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /14 pts 2. /10 pts 3. /8 pts 4 /8 pts 5. /12 pts 6. /8 pts
More informationOne-Compartment Open Model: Intravenous Bolus Administration:
One-Compartment Open Model: Intravenous Bolus Administration: Introduction The most common and most desirable route of drug administration is orally by mouth using tablets, capsules, or oral solutions.
More informationPHAR 7632 Chapter 7. Table Market and Share of Pharmaceuticals by ROA Data from Viswanathan, 2004
Student Objectives for this Chapter After completing the material in this chapter each student should:- be able to describe various routes of drug administration including the concentration versus time
More informationDEVELOPMENT OF IN VITRO-IN VIVO CORRELATION FOR ENCAPSULATED METOPROLOL TARTRATE
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 70 No. 4 pp. 743ñ747, 2013 ISSN 0001-6837 Polish Pharmaceutical Society DEVELOPMENT OF IN VITRO-IN VIVO CORRELATION FOR ENCAPSULATED METOPROLOL TARTRATE
More informationPHA Final Exam Fall 2006
PHA 5127 Final Exam Fall 2006 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationDespite the widespread use of triptans ... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability
... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability Randal L. Von Seggern, PharmD, BCPS Abstract Objective: This article summarizes preclinical and clinical data for
More informationPharmacokinetics Applied to the Treatment of Asthma
Pharmacokinetics Applied to the Treatment of Asthma 2016 edition by David C. McMillan, PhD Department of Pharmacology and Experimental Neuroscience College of Medicine University of Nebraska Medical Center
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2011 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationPharmacokinetics Overview
Pharmacokinetics Overview Disclaimer: This handout and the associated lectures are intended as a very superficial overview of pharmacokinetics. Summary of Important Terms and Concepts - Absorption, peak
More informationMedication Administration. By: Carolyn McCune RN, BSN, MSN, CRNP
Medication Administration By: Carolyn McCune RN, BSN, MSN, CRNP Percutaneous Administration Medications application to the skin or mucus membranes Ointments, creams, powders, lotions, solutions into the
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationMethylergometrine, an active metabolite of methysergide
Methylergometrine, an active metabolite of methysergide Else Muller-Schweinitzer, Carlo Tapparelli CEPWGA Miiller-Schweinitzer E, Tapparelli C. Methylergometrine, an active metabolite of methysergide.
More informationGlaxoSmithKline. Renal impairment. Hepatic impairment
RELENZA GlaxoSmithKline Zanamivir QUALITATIVE AND QUANTITATIVE COMPOSITION Each RELENZA ROTADISK consists of four regularly spaced double foil blisters each containing a white to off-white micronised powder
More informationHowida Kamal, Ph.D Ass. Prof. of Pharmaceutics, Cairo University
Pharmacy Howida Kamal, Ph.D Ass. Prof. of Pharmaceutics, Cairo University Pharmacy Pharmacy Pharmaceutics The science of dosage form design. Pharmacy 1. 2. 3. Dosage forms Information Resources Use of
More informationCONTROLLED-RELEASE & SUSTAINED-RELEASE DOSAGE FORMS. Pharmaceutical Manufacturing-4
CONTROLLED-RELEASE & SUSTAINED-RELEASE DOSAGE FORMS Pharmaceutical Manufacturing-4 The improvement in drug therapy is a consequence of not only the development of new chemical entities but also the combination
More informationPHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 4120 Second Exam Key Fall 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /10 ponts 2. /20 points 3. /10 points 4. /10 points
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen This full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/14779
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 120 No 1267 ISSN 1175 8716 Is Salamol less effective than Ventolin? A randomised, blinded, crossover study in New Zealand Catherina L Chang, Manisha Cooray, Graham Mills,
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationCell Membranes, Epithelial Barriers and Drug Absorption p. 1 Introduction p. 2 The Plasma Membrane p. 2 The phospholipid bilayer p.
Cell Membranes, Epithelial Barriers and Drug Absorption p. 1 Introduction p. 2 The Plasma Membrane p. 2 The phospholipid bilayer p. 3 Dynamic behaviour of membranes p. 4 Modulation of membrane fluidity
More informationIntrasubject Variation in Elimination Half-Lives of Drugs Which Are Appreciably Metabolized
Journal of Pharmacokinetics and Biopharrnaceutics, Vol. 1, No. 2, 1973 SCIENTIFIC COMMENTARY Intrasubject Variation in Elimination Half-Lives of Drugs Which Are Appreciably Metabolized John G. Wagner 1
More informationRESPIRATORY PHARMACOLOGY - ASTHMA. Primary Exam Teaching - Westmead ED
RESPIRATORY PHARMACOLOGY - ASTHMA Primary Exam Teaching - Westmead ED Sympathomimetic agents MOA: relax airway smooth muscle and inhibit broncho constricting mediators from mast cells May also inhibit
More informationDOMPERIDONE BNF 4.6. Domperidone is a dopamine type 2-receptor antagonist. It is structurally related to the
DOMPERIDONE BNF 4.6 Class: Prokinetic anti-emetic. Indications: Nausea and vomiting, dysmotility dyspepsia, gastro-oesophageal reflux. Pharmacology Domperidone is a dopamine type 2-receptor antagonist.
More informationClinical Trials A Practical Guide to Design, Analysis, and Reporting
Clinical Trials A Practical Guide to Design, Analysis, and Reporting Duolao Wang, PhD Ameet Bakhai, MBBS, MRCP Statistician Cardiologist Clinical Trials A Practical Guide to Design, Analysis, and Reporting
More informationChapter 7. Principles of Pharmacology
Chapter 7 Principles of Pharmacology Introduction Administering medications is a serious business. Medications may alleviate pain and improve patient s well-being. Used inappropriately, may cause harm
More informationPsychopharmacology part 1
Psychopharmacology part 1 D mary ET Boyle, Ph.D. Cognitive S UCSD Department of Cognitive Science Pharmacology is the study of drug effect on living systems C. Elegans How are drugs used to understand
More informationUnderstand the physiological determinants of extent and rate of absorption
Absorption and Half-Life Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand Objectives Understand the physiological determinants of extent and rate of absorption
More informationBasic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics
Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe
More informationSaliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System
Drugs R D (2015) 15:79 83 DOI 10.1007/s40268-015-0080-1 ORIGINAL RESEARCH ARTICLE Saliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion
More informationIntroduction. Keywords: ergotamine, migraine, peripheral arteries, rizatriptan
The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects Peer Tfelt-Hansen, 1 Kaj Seidelin, 1 Michael
More informationDEFINITIONS. Pharmacokinetics. Pharmacodynamics. The process by which a drug is absorbed, distributed, metabolized and eliminated by the body
PHARMACOLOGY BASICS DEFINITIONS Pharmacokinetics The process by which a drug is absorbed, distributed, metabolized and eliminated by the body Pharmacodynamics The interactions of a drug and the receptors
More informationCurrent Challenges and Opportunities in Demonstrating Bioequivalence
Current Challenges and Opportunities in Demonstrating Bioequivalence Gur Jai Pal Singh, Ph.D. Watson Laboratories, Inc. Corona, California, USA Demonstrating Bioequivalence of Locally Acting Orally Inhaled
More informationDisposition of metronidazole and its effects on sulphasalazine
Br. J. clin. Pharmac. (1986), 21, 431-435 Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease J. L. SHAFFER*,' A. KERSHAW2 & J. B. HOUSTON2
More informationIntroduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects
More informationLESSON ASSIGNMENT. After completing this lesson, you should be able to:
LESSON ASSIGNMENT LESSON 11 Oxytocics and Ergot Alkaloids. LESSON ASSIGNMENT Paragraphs 11-1 through 11-13. LESSON OBJECTIVES After completing this lesson, you should be able to: 11-1. Given a group of
More informationIntroduction pharmacology and drug administration
1 Introduction to pharmacology and drug administration INTRODUCTION Pharmacology is the study of drugs or chemicals used to treat and cure disease and their interactions in the body. Within the study of
More informationPredictive modeling of deposition, dissolution, absorption and systemic exposure
Predictive modeling of deposition, dissolution, absorption and systemic exposure IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Per Bäckman and Bo Olsson, AstraZeneca R&D, Mölndal Sweden The views
More informationAEROSOL THERAPY: THE PRACTICALITIES
AEROSOL THERAPY: THE PRACTICALITIES Lester I. Harrison, PhD Section Head, Clinical Pharmacokinetics, 3M Pharmaceuticals, 3M Center 270-3S-05, St. Paul, MN, USA 55144 liharrison@mmm.com Introduction: Horses,
More informationAbortive Agents. Available Strengths. Formulary Limits. Tablet: 5mg, 10mg ODT: 5mg, 10 mg 25mg, 50mg, 100mg. 5mg/act, 20mg/act
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 9/12/2017 CLASS: Neurological Disorders REVIEW HISTORY 12/16, 9/15, 2/15, 2/10, 5/07 LOB: MCL
More informationpharmacokinetics and tolerability of rizatriptan in healthy
Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers Y. Lee, 1 J. A. Conroy, 2 M. E. Stepanavage, 3 C. M. Mendel, 2 G. Somers, 4 D. A. McLoughlin, 1 T. V. Olah, 1
More informationDoes repeated subcutaneous administration of sumatriptan produce an unfavorable evolution in cluster headache?
J Headache Pain (2004) 5:110 114 DOI 10.1007/s10194-004-0078-5 ORIGINAL Virginie Dousset Virginie Chrysostome Bruno Ruiz S. Irachabal Magalie Lafittau Françoise Radat Bruno Brochet Patrick Henry Does repeated
More informationBioequivalence of Inhaled Corticosteroids. -with emphasis on Pharmacokinetic Tools.
Bioequivalence of Inhaled Corticosteroids -with emphasis on Pharmacokinetic Tools? hochhaus@ufl.edu Topics related to Bioequivalence 10-60 % Deposited in lung Complete absorption from the lung Cl muc Mouth
More informationZolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice
J Headache Pain (2004) 5:237 242 DOI 10.1007/s10194-004-0132-3 ORIGINAL Carl G.H. Dahlöf Mattias Linde Erika Kerekes Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred
More informationA Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl Citrate
Vol. 26 No. 2 August 2003 Journal of Pain and Symptom Management 743 Original Article A Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl
More informationIt is recommended that a mask and protective eyewear be worn when providing care to a patient with a cough
UNIVERSITY HEALTH NETWORK POLICY #: PAGE 1 OF 7 POLICY AND PROCEDURE MANUAL: RESPIRATORY THERAPY DEPT PATIENT CARE SECTION ORIGINAL DATE: 04/03 ISSUED BY: SITE LEADER APPROVED BY: Infection Prevention
More informationL. Thorsson, S. Edsbäcker, T-B. Conradson
Eur Respir J, 1994, 7, 1839 1844 DOI: 10.1183/09031936.94.07101839 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1994 European Respiratory Journal ISSN 0903-1936 Lung deposition of budesonide
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2010 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationQ. What are metered-dose inhalers? A. These are devices that dispense medicines directly into the lungs, in the form of a mist or aerosol in a
1 2 Q. What are metered-dose inhalers? A. These are devices that dispense medicines directly into the lungs, in the form of a mist or aerosol in a specific dosage. In an MDI, the medicine is suspended
More information2- Minimum toxic concentration (MTC): The drug concentration needed to just produce a toxic effect.
BIOPHARMACEUTICS Drug Product Performance Parameters: 1- Minimum effective concentration (MEC): The minimum concentration of drug needed at the receptors to produce the desired pharmacologic effect. 2-
More informationChapter 11 - Principles of Pharmacology
1 2 3 4 5 6 7 8 9 Chapter 11 Principles of Pharmacology National EMS Education Standard Competencies (1 of 5) Pharmacology Applies fundamental knowledge of the medications that the EMT may assist/administer
More informationMOD 4: Medication Administration
NSE22 Page 1 1. MOD 4: Medication Administration October1310 8:12 PM The CNO identifies eight rights of medication administration. Identify the eight rights and the rationale for each Right Client give
More informationEffect of Septilin A Herbal Preparation on Pharmacokinetics of Carbamazepine in Rabbits
[Indian Journal of Physiology and Pharmacology (1998): (42), 4, 527] Effect of Septilin A Herbal Preparation on Pharmacokinetics of Carbamazepine in Rabbits Garg, S.K., Afm. S. Islam and Naresh Kumar Department
More informationPublic Assessment Report Scientific discussion. Salmeterol/Fluticasone Sandoz (salmeterol xinafoate, fluticasone propionate) SE/H/1323/03/DC
Public Assessment Report Scientific discussion Salmeterol/Fluticasone Sandoz (salmeterol xinafoate, fluticasone propionate) SE/H/1323/03/DC This module reflects the scientific discussion for the approval
More informationUsing Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop
Using Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop Topics to be Addressed Why AMS? AMS for mass balance studies with vismodegib AMS for absolute bioavailability
More informationN-monodesmethyldiltiazem is the predominant metabolite of
Br. J. clin. Pharmac. (1987), 24, 185-189 N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives S. C. MONTAMAT & D. R. ABERNETHY Section on
More informationBioavailability and Pharmacokinetics of Isradipine after Oral and Intravenous Administration: Half-Life Shorter than Expected?
C Pharmacology & Toxicology 2000, 86, 178 182. Printed in Denmark. All rights reserved Copyright C ISSN 0901-9928 Bioavailability and Pharmacokinetics of Isradipine after Oral and Intravenous Administration:
More informationNICOTINE PHARMACOLOGY and PRINCIPLES of ADDICTION. 3 rd of 3 Prep for Session 1
NICOTINE PHARMACOLOGY and PRINCIPLES of ADDICTION 3 rd of 3 Prep for Session 1 CHEMISTRY of NICOTINE Pyridine ring N H N CH 3 Pyrrolidine ring Nicotiana tabacum Natural liquid alkaloid Colorless, volatile
More informationThe best defense is a good offense. Optimizing the Acute Treatment of Migraine. Disclosures 11/10/2017
Optimizing the Acute Treatment of Migraine Brian M. Plato, DO, FAHS Norton Neuroscience Institute Louisville, KY Disclosures Speakers Bureau (personal): Allergan, Depomed, Avanir Research Funding (paid
More informationEffect of particle size of bronchodilator aerosols on lung distribution and pulmonary function in patients
Thorax 1987;42:457-461 Effect of particle size of bronchodilator aerosols on lung distribution and pulmonary function in patients with chronic asthma D M MITCHELL, M A SOLOMON, S E J TOLFREE, M SHORT,
More informationits short- and long-term therapeutic efficacy
Lithium carbonate in cluster headache: assessment of its short- and long-term therapeutic efficacy Gian Camillo Manzoni, Giorgio Bono, Marina Lanfranchi, Giuseppe Micieli, Mario Giovanni Terzano and Giuseppe
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPHARMACOKINETICS SMALL GROUP II:
PHARMACOKINETICS SMALL GROUP II: Question 1 Why are some drug therapies initiated with a loading dose? Emphasize that LD establishes initial therapeutic level quickly. The time to reach the steady-state
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 September 22.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1990 February ; 22(1): 57 59. Effect of Hepatic Dysfunction and T Tube Clamping on FK 506 Pharmacokinetics and Trough
More informationWHY INTRAMUSCULAR METHOTREXATE MAY BE MORE EFFICACIOUS THAN ORAL DOSING IN PATIENTS WITH RHEUMATOID ARTHRITIS
British Journal of Rheumatology 1997;36:86 90 WHY INTRAMUSCULAR METHOTREXATE MAY BE MORE EFFICACIOUS THAN ORAL DOSING IN PATIENTS WITH RHEUMATOID ARTHRITIS R. A. HAMILTON and J. M. KREMER Albany College
More informationSlide 1. Slide 2. Slide 3. Drug Action and Handling. Lesson 2.1. Lesson 2.1. Drug Action and Handling. Drug Action and Handling.
Slide 1 Drug Action and Handling Chapter 2 1 Slide 2 Lesson 2.1 Drug Action and Handling 1. Differentiate dose, potency, and efficacy in the context of the actions of drugs. 2. Explain the pharmacologic
More informationResearch Envisaged and Selection of Drug Candidate
Chapter-3 Research Envisaged and Selection of Drug Candidate 3.1 OBJECTIVE OF THE STUDY The objective of this project is to a. Formulate Mouth Dissolving Tablet (MDTs) by using model drugs By different
More informationDisclosures. Triptans for Kids 5/16/13
5/16/13 Disclosures Triptans for Kids Amy A. Gelfand, MD GelfandA@neuropeds.ucsf.edu Departments of Neurology and Pediatrics UCSF Child Neurology and Headache Center I receive grant funding from: NIH/NINDS
More informationPHA Final Exam Fall 2001
PHA 5127 Final Exam Fall 2001 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points 1. /12 pts 2. /8 pts 3. /12 pts 4. /20 pts 5. /27 pts 6. /15
More informationDr. M.Mothilal Assistant professor
Dr. M.Mothilal Assistant professor Bioavailability is a measurement of the rate and extent of drug that reaches the systemic circulation from a drug product or a dosage form. There are two different types
More informationIndividual Study Table Referring to Part of the Dossier. Volume:
Final Report M/100977/21Final Version () 2. SYNOPSIS A Title of Study: A PHASE IIa, RANDOMISED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO CONTROLLED, 3 PERIOD CROSS-OVER, ASCENDING DOSE CLINICAL TRIAL TO ASSESS
More informationMedication For Migraine Chart: Table 1: Acute Treatment when the attack begins
Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins Page a Analgesics (painkillers) Non-steroidal antiinflammatory drugs (NSAIDs) Prescription required Brand Name Formulation
More informationDrug Class Review on Triptans
Drug Class Review on UPDATED FINAL REPORT #1 December 2003 Mark Helfand, MD, MPH Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Table of Contents Introduction
More information